Metropolitan Life Insurance Company (MetLife)’s Minerva Neurosciences NERV Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio NERV Stock Details NERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-289	Closed	-$13.9K	–	2573
2020 Q1	$13.9K	Buy	+289	New	+$17.4K	﹤0.01%	2468
2019 Q4	–	Sell	-1,416	Closed	-$87.8K	–	2551
2019 Q3	$87.8K	Sell	1,416 -34	-2%	-$1.93K	﹤0.01%	2367
2019 Q2	$65.3K	Hold	1,450	–	–	﹤0.01%	2465
2019 Q1	$91.2K	Buy	1,450 +11	+0.8%	+$661	﹤0.01%	2365
2018 Q4	$77.6K	Hold	1,439	–	–	﹤0.01%	2430
2018 Q3	$145K	Hold	1,439	–	–	﹤0.01%	2225
2018 Q2	$95K	Buy	+1,439	New	+$87.4K	﹤0.01%	2347
2017 Q3	–	Sell	-2,397	Closed	-$170K	–	2506
2017 Q2	$170K	Buy	+2,397	New	+$155K	﹤0.01%	2432
2017 Q1	–	Sell	-2,015	Closed	-$189K	–	2537
2016 Q4	$189K	Hold	2,015	–	–	﹤0.01%	2381
2016 Q3	$227K	Buy	+2,015	New	+$196K	﹤0.01%	2255

Other funds holding NERV

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s NERV Position: Q2 2020 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Minerva Neurosciences (NERV) in Q2 2020, closing a stake of 289 shares — an estimated $13.9K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in NERV in Q3 2016 and held it in 10 quarters. The position peaked at $227K in Q3 2016. 80 funds tracked by Wall St. Rank hold NERV as of Q2 2020.

Metropolitan Life Insurance Company (MetLife) reported no remaining Minerva Neurosciences position as of Q2 2020 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 289 Minerva Neurosciences shares in Q2 2020, an estimated $13.9K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Minerva Neurosciences in Q3 2016 and held it in 10 quarters.
Metropolitan Life Insurance Company (MetLife)'s Minerva Neurosciences position peaked at $227K in Q3 2016.
80 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2020.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2020, filed 14 Aug 2020.